Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Henry Chen
AddedMar 31, 2024
UpdatedMay 31, 2026
Henry Chen

Henry Chen

Founder, Curamir Therapeutics

Crunchbase

Henry Chen's Career

Curamir Therapeutics
Curamir Therapeutics

Woburn, MA, US

Founder
Antios Therapeutics
Antios Therapeutics

Atlanta, GA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Henry Chen's Career

Curamir Therapeutics
Curamir Therapeutics
Series A$10M62019Woburn, MA, US
Founder

Similar to Curamir Therapeutics

CurisCurisCambridge, MA, USCancer Therapiesest. 2000CurisCambridge, MA, US · est. 2000

Curis, a US-based company, innovates in cancer drug development, leveraging signaling pathway technologies for targeted therapies.

Public · $174.1M100
Curie.BioCurie.BioBoston, MA, USDrug Developmentest. 2022Curie.BioBoston, MA, US · est. 2022

Curie.Bio: A seed-stage venture firm specializing in drug-focused services for founders.

Series B26
Combined TherapeuticsCombined TherapeuticsBoston, MA, USCancer Therapies, MRNA Vaccinesest. 2016Combined TherapeuticsBoston, MA, US · est. 2016

CTx: Pioneering pre-clinical biotech for intelligent, next-gen mRNA therapies.

Seed · $250k15
Antios Therapeutics
Antios Therapeutics
Public$200.4M352018Atlanta, GA, US
Board Member· Board

Leadership at Antios Therapeutics

Greg MayesGreg MayesCEO
Idean MarvastyIdean MarvastyCo-Founder
Abel De La RosaAbel De La RosaBoard Member
Douglas MayersDouglas MayersCo-Founder
Scott MorensteinScott MorensteinBoard Member
Nicole VitulloNicole VitulloBoard Member

Similar to Antios Therapeutics

Aligos TherapeuticsAligos TherapeuticsSan Francisco, CA, USAntivirals, Therapeuticsest. 2018Aligos TherapeuticsSan Francisco, CA, US · est. 2018

Aligos Therapeutics: A leading biopharmaceutical firm specializing in antiviral therapies and liver disease treatment.

Public · $400.6M92
Antiva BiosciencesAntiva BiosciencesSouth San Francisco, CA, USAntiviral Therapiesest. 2012Antiva BiosciencesSouth San Francisco, CA, US · est. 2012

Antiva Biosciences, a biopharmaceutical firm, pioneers antiviral therapies targeting HPV, HIV, and more.

Series E · $140.3M24
RetroviroxRetroviroxSan Diego, CA, USAntiviral, Therapiesest. 2008RetroviroxSan Diego, CA, US · est. 2008

RetroVirox, a San Diego-based biotech firm, innovates in antiviral treatments and offers cell-based screening services.

Seed · $3M5
Anthos TherapeuticsAnthos TherapeuticsCambridge, MA, USBiopharmaceuticalsest. 2018Anthos TherapeuticsCambridge, MA, US · est. 2018

Anthos Therapeutics: Advancing CVM disease care through innovative, validated biopharmaceutical therapies.

Series A · $250M33

Henry Chen's Similar Executives & Operators

Soemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiBo ZhangBo ZhangCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance Retail

People Similar to Henry Chen

Tasneem DohadwalaTasneem DohadwalaBoard Member · InstyllaChen YuChen YuFounder · TCG Crossover ManagementBrian KangBrian KangCo-Founder · Nautilus Venture PartnersMichael YangMichael YangBoard Member · Kiwi CrateKenneth PelowskiKenneth PelowskiBoard Member · Cobalt TechnologiesChristopher E. CavanaghChristopher E. CavanaghBoard Member · dscout